2019年共享临床决策建议后65岁及以上医疗保险受益人中13价肺炎球菌结合疫苗接种情况
研究利用2018年1月至2020年9月医疗保险可识别文件,分析65岁及以上按服务收费受益人中肺炎球菌疫苗月度接种率。结果显示,共享临床决策建议实施后,PCV13接种占比从70%以上降至60%以下,免疫功能低下者和脆弱亚组也出现类似下降。
要点
- 共享临床决策建议实施后,PCV13接种占比从70%以上降至60%以下。
- 免疫功能低下者和脆弱亚组的PCV13接种下降趋势一致。
- 尽管免疫功能低下者仍被常规推荐接种PCV13,其接种率也下降。
核心结论
- 共享临床决策建议实施后,PCV13接种占比从70%以上降至60%以下,免疫功能低下者和脆弱亚组也出现类似下降。
主要发现
- 共享临床决策建议实施前,PCV13占肺炎球菌疫苗接种的70%以上;实施后(2020年2月起)降至60%以下。
- PCV13接种下降在脆弱亚组和免疫功能低下者中表现一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In November 2019, the US Advisory Committee on Immunization Practices recommended shared clinical decision-making (SCDM) for use of 13-valent pneumococcal conjugate vaccine (PCV13) among immunocompetent elderly adults. The impact of SCDM on PCV13 use in this population, immunocompromised persons, and vulnerable subgroups has not been well documented. METHODS: Using Medicare Research Identifiable Files (01/2018 - 09/2020), monthly uptake of pneumococcal vaccine (PCV13, 23-valent pneumococcal polysaccharide vaccine [PPSV23]) was identified among fee-for-service beneficiaries aged ≥ 65 years with Part B coverage and no evidence of prior PCV13. Uptake was stratified by vaccine, risk profile, and demographics. RESULTS: Among the > 12 M beneficiaries included each month, PCV13 uptake declined from > 70% of pneumococcal vaccinations before SCDM to < 60% after SCDM (02/2020). Reductions in PCV13 uptake were consistent across vulnerable subgroups as well as immunocompromised persons. CONCLUSIONS: PCV13 use decreased among immunocompetent and immunocompromised persons alike, despite continued routine PCV13 recommendation for the latter group.
引用
- Vietri J, Sato R, Averin A, et al. Pneumococcal vaccine uptake among Medicare Beneficiaries aged ≥65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019. Vaccine. 2023. PMID: 37474408. doi:10.1016/j.vaccine.2023.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。